AU2001257903A1 - Method for treatment of neurodegenerative diseases - Google Patents

Method for treatment of neurodegenerative diseases

Info

Publication number
AU2001257903A1
AU2001257903A1 AU2001257903A AU5790301A AU2001257903A1 AU 2001257903 A1 AU2001257903 A1 AU 2001257903A1 AU 2001257903 A AU2001257903 A AU 2001257903A AU 5790301 A AU5790301 A AU 5790301A AU 2001257903 A1 AU2001257903 A1 AU 2001257903A1
Authority
AU
Australia
Prior art keywords
treatment
neurodegenerative diseases
neurodegenerative
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257903A
Inventor
Tae-Wan Kim
Rudolph E Tanzi
Andrew S. Yoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2001257903A1 publication Critical patent/AU2001257903A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001257903A 2000-03-22 2000-07-25 Method for treatment of neurodegenerative diseases Abandoned AU2001257903A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19110900P 2000-03-22 2000-03-22
US60191109 2000-03-22
PCT/US2000/020138 WO2001071351A1 (en) 2000-03-22 2000-07-25 Method for treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AU2001257903A1 true AU2001257903A1 (en) 2001-10-03

Family

ID=22704180

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257903A Abandoned AU2001257903A1 (en) 2000-03-22 2000-07-25 Method for treatment of neurodegenerative diseases

Country Status (3)

Country Link
US (1) US20020015941A1 (en)
AU (1) AU2001257903A1 (en)
WO (1) WO2001071351A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02009756A (en) * 2000-04-03 2003-06-17 Bristol Myers Squibb Co Isolation of functionally active gamma secretase protein complex and methods for detection of activity and inhibitors thereof.
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
TW201424770A (en) 2003-02-14 2014-07-01 Childrens Hosp & Res Ct Oak Lipophilic drug delivery vehicle and methods of use thereof
EP1858325A4 (en) * 2005-01-07 2010-06-30 Roskamp Res Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
PL1954718T3 (en) 2005-11-30 2015-04-30 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
JP5486808B2 (en) 2005-11-30 2014-05-07 アッヴィ・インコーポレイテッド Monoclonal antibody against amyloid beta protein and use thereof
EP1993548A2 (en) * 2006-03-01 2008-11-26 Roskamp Research LLC Compounds for inhibiting beta-amyloid production
GB0606015D0 (en) 2006-03-28 2006-05-03 Merck Sharp & Dohme therapeutic agents
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2120557A4 (en) * 2006-12-08 2010-02-10 Roskamp Res Llc Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
US20100204230A1 (en) 2007-02-12 2010-08-12 Peter Blurton Piperazine derivatives for treatment of ad and related conditions
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
US8575150B2 (en) 2008-12-16 2013-11-05 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of Alzheimer's disease
CN104744591B (en) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 Amyloid beta binding proteins
CN105348387B (en) 2010-08-14 2020-08-25 Abbvie 公司 Amyloid beta binding proteins
GB201212334D0 (en) 2012-07-11 2012-08-22 Warwick The Therapeutic targets for alzheimers disease
AU2014101153A4 (en) * 2014-01-03 2014-10-23 Macau University Of Science And Technology A Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932417A (en) * 1996-10-15 1999-08-03 The Regents Of The University Of California Method of screening compounds for controlling capacitative calcium ion entry into mammalian cells

Also Published As

Publication number Publication date
US20020015941A1 (en) 2002-02-07
WO2001071351A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002243231A1 (en) Method of treating autoimmune diseases
AU1294401A (en) Methods for treating fibroproliferative diseases
HUP0203803A3 (en) Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
AU2001257903A1 (en) Method for treatment of neurodegenerative diseases
AU2001288271A1 (en) Methods for treating inflammatory diseases
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2001286983A1 (en) Method of treatment
AU2001285747A1 (en) Method for the treatment of tobacco
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
AU2002229986A1 (en) Method of treating neurological diseases
AU4215499A (en) Treatment of neurodegenerative diseases
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU2001262177A1 (en) Method of treatment
AU2002225327A1 (en) Apparatus for aesthetic treatment
AU2003291730A1 (en) Methods and compositions for treating neurodegenerative diseases
AUPR536401A0 (en) Method for treatment of waste water
AUPR731901A0 (en) Method of treatment
AU1405001A (en) Treatment of diseases
AU5854799A (en) Novel treatment of neurodegenerative diseases
AU4598400A (en) Method of treatment
AU2001253560A1 (en) Methods of treatment
AU2001262252A1 (en) Means for treating attacks of auto-immune diseases
AUPQ662500A0 (en) Method of treatment
AUPQ949500A0 (en) Method of treatment